Rfg Advisory, LLC Vertex Pharmaceuticals Inc Transaction History

Rfg Advisory, LLC

$3.18 Billion
Q3 2024

A detailed history of Rfg Advisory, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Rfg Advisory, LLC holds 1,676 shares of VRTX stock, worth $778,602. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,676

Previous 1,432 17.04%

Holding current value

$778,602

Previous $671,000 16.1%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	BUY	$460.0 - $505.78 $112,240 - $123,410	244 Added 17.04%	1,676 $779,000
Q2 2024 Jul 15, 2024	BUY	$392.81 - $485.53 $6,677 - $8,254	17 Added 1.2%	1,432 $671,000
Q1 2024 Apr 11, 2024	BUY	$407.69 - $446.08 $134,945 - $147,652	331 Added 30.54%	1,415 $591,000
Q4 2023 Jan 25, 2024	BUY	$343.0 - $410.68 $77,861 - $93,224	227 Added 26.49%	1,084 $441,000
Q3 2023 Oct 16, 2023	BUY	$338.18 - $362.46 $7,439 - $7,974	22 Added 2.63%	857 $298,000
Q2 2023 Aug 03, 2023	BUY	$314.42 - $351.91 $22,323 - $24,985	71 Added 9.29%	835 $293,000
Q1 2023 May 09, 2023	BUY	$283.23 - $323.1 $216,387 - $246,848	764 New	764 $240,000
Q4 2019 Jan 22, 2020	SELL	$166.71 - $223.91 $290,075 - $389,603	-1,740 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $19,615 - $22,076	118 Added 7.27%	1,740 $295,000
Q2 2019 Aug 23, 2019	BUY	$164.61 - $190.37 $16,461 - $19,037	100 Added 6.57%	1,622 $300,000
Q2 2019 Aug 15, 2019	BUY	$164.61 - $190.37 $250,536 - $289,743	1,522 New	1,522 $282,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rfg Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rfg Advisory, LLC with notifications on news.

Account